Physician profile
Premila Bhat
NPI 1083818546
$1,889.92
in general payments reported to CMS, 2019-2025
15 companies · $888 in 2025
The $888 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $107 · 2021: $441 · 2022: $51.77 · 2023: $133 · 2024: $97.29 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $572 · Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $572.18 |
| Food and Beverage | $546.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $844.78 | 2025 | Renal - Chronic |
| Janssen Pharmaceuticals, INC | $262.50 | 2019-2022 | |
| Abbvie INC. | $215.11 | 2021-2024 | |
| Glaxosmithkline, LLC. | $102.90 | 2023 | Benlysta |
| Emd Serono, INC. | $85.83 | 2021 | |
| Gilead Sciences, INC. | $77.00 | 2021-2024 | |
| Shire North American Group INC | $73.74 | 2019 | |
| Gastroklenz, INC. Dba Cloudcath | $56.59 | 2024 | |
| Insmed, INC. | $36.36 | 2019 | |
| Dynavax Technologies Corporation | $29.78 | 2023 | Heplisav-B |
| E.R. Squibb & Sons, L.L.C. | $25.05 | 2019-2020 | |
| Melinta Therapeutics, LLC | $23.62 | 2021 | |
| Renalytix Ai, INC. | $22.71 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Akebia Therapeutics INC | $20.75 | 2025 | Vafseo |
| Rockwell Medical, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Premila Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.